We assess the effectiveness, costs and broader impact of health care interventions including tests, pharmaceuticals, devices and procedures.
Most of our HTA work is carried out as part of the NIHR Technology Assessment Reviews (TAR) programme. The programme enables rapid commissioning of HTAs including systematic reviews and economic evaluations to inform NHS decision makers. These include the National Institute for Health and Care Excellence (NICE) technology appraisal programme, NICE highly specialised technologies programme, NICE diagnostic assessment programme, and other NHS bodies.
TARs address important decision problems facing the NHS, providing transparent and robust assessments of the clinical and cost effectiveness of relevant technologies. TARs are based on high quality evidence syntheses including systematic reviews and decision modelling as appropriate. They identify, critique, and highlight strengths and weaknesses of the underpinning research studies and data are synthesised using appropriate methods, with uncertainty presented clearly. See our listing of TAR projects to find out our current and completed work in this area.
In addition to TAR assessments we are also undertaking a number of other projects funded by the NIHR HTA program. This currently includes:
We are currently undertaking an IPD meta-analysis evaluating progestogen for prevention of preterm birth, funded by PCORI.
Recently completed projects include a NIHR directly funded project, “Interventional management of hyperhidrosis: a systematic review and value of information analysis” (HTA 14/211/02).
The clinical and cost effectiveness of inotuzumab ozogamicin for the treatment of adult relapsed or refractory b-cell acute lymphoblastic leukaemia: an Evidence Review Group evaluation of a NICE Single Technology Appraisal